Plain-English translation of NCT06488222 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two medications— and —that are placed directly into your bladder through a catheter to help prevent early-stage bladder cancer from returning. Most people newly diagnosed with this type of bladder cancer currently receive a different treatment called BCG, but researchers want to see if this new combination might work better for certain patients. This medication is given in two phases: an initial treatment period followed by ongoing maintenance doses over up to a year.
Many patients with early-stage, intermediate-risk bladder cancer experience their cancer coming back, even after standard treatment. Researchers hope this new treatment approach will reduce the chance of recurrence and give patients a better outcome.
You likely qualify if…
You likely don't qualify if…
You would first have a procedure to remove the visible tumor from your bladder (transurethral resection). Then, you would receive the new medication through a catheter placed into your bladder once a week for six weeks during an initial phase, followed by monthly treatments for up to 12 months. You would need regular follow-up visits and cystoscopy exams to monitor how well the treatment is working and to check for any signs of cancer returning.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States